GSK046 (40mg/kg/QD; s.c. for 14 days) has immunomodulatory activity[1].
GSK046 exhibits Cmax (C57BL6 1589, C57B16 2993 ng/mL) and terminal elimination half-lives (C57BL6 1.8, C57B16 1.9 h) following oral administration (C57BL6 10, C57B16 40 mg/kg)[1].
GSK046 exhibits Cmax (mouse 1589, rat 202 ng/mL) and terminal elimination half-lives (mouse 1.8, rat 1.4 h) following oral administration (mouse 10, rat 10 mg/kg)[1].
| Animal Model: | Male C57BL/6 mice (8/10-weeks-old) are injected with keyhole limpet hemocyanin (KLH)[1] |
| Dosage: | 40mg/kg/QD |
| Administration: | S.c. injections for 14 days |
| Result: | Reduced the production of anti-keyhole limpet hemocyanin (KLH) IgM and was well tolerated. |
| Animal Model: | Female C57BL/6 mice[1] |
| Dosage: | 10mg/kg (Pharmacokinetic Analysis) |
| Administration: | Oral administration |
| Result: | Cmax (1859 ng/mL), T1/2 (1.8 h). |
| Animal Model: | Male C57BL/6 mice[1] |
| Dosage: | 40mg/kg (Pharmacokinetic Analysis) |
| Administration: | Oral administration |
| Result: | Cmax (2993 ng/mL), T1/2 (1.9 h). |
| Animal Model: | Female Lewis rat[1] |
| Dosage: | 10mg/kg (Pharmacokinetic Analysis) |
| Administration: | Oral administration |
| Result: | Cmax (202 ng/mL), T1/2 (1.4 h). |
![Benzamide, 4-?(acetylamino)?-?3-?fluoro-?N-?(trans-?4-?hydroxycyclohexyl)?-?5-?[(1S)?-?1-?phenylethoxy]?- Structure](/CAS/20210111/GIF/2474876-09-8.gif)
